The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Statin therapy increases lipoprotein(a) levels
Abstract
Aims: Lipoprotein(a) [Lp(a)] is elevated in 20–30% of people. This study aimed to assess the effect of statins on Lp(a) levels. Methods and results: This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six randomized trials, three statin-vs.-placebo trials, and three statin-vs.-statin trials, with pre- and on-treatment (4–104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day, rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. Lipoprotein(a) levels were measured with the same validated assay. The primary analysis of Lp(a) is based on the log-transformed data. In the statin-vs.-placebo pooled analysis, the ratio of geometric means [95% confidence interval (CI)] for statin to placebo is 1.11 (1.07–1.14) (P < 0.0001), with ratio >1 indicating a higher increase in Lp(a) from baseline in statin vs. placebo. The mean percent change from baseline ranged from 8.5% to 19.6% in the statin groups and −0.4% to −2.3% in the placebo groups. In the statin-vs.-statin pooled analysis, the ratio of geometric means (95% CI) for atorvastatin to pravastatin is 1.09 (1.05–1.14) (P < 0.0001). The mean percent change from baseline ranged from 11.6% to 20.4% in the pravastatin group and 18.7% to 24.2% in the atorvastatin group. Incubation of HepG2 hepatocytes with atorvastatin showed an increase in expression of LPA mRNA and apolipoprotein(a) protein. Conclusion: This meta-analysis reveals that statins significantly increase plasma Lp(a) levels. Elevations of Lp(a) post-statin therapy should be studied for effects on residual cardiovascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intriguingly, a recent study also found that statin treatment caused a significant increase in LPA expression in HepG2 cells19.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [19]
In the citing paper
“Statin usage has been associated with increased circulating Lp(a) levels and we did find increased rates of this medication among pathogenic LDLR allele carriers.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [19]
In the citing paper
“However, the association between these alleles and Lp(a) remained significant after adjusting Lp(a) levels for statin usage across the entire 95% confidence interval for this effect19.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [19]
In the citing paper
“the association between Lp(a) levels and LDLR genotype remained statistically significant after conservatively adjusting for statin effects based on the boundaries of the 95% confidence interval for their effect size in a recent meta-analysis of 5256 individuals19”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [19]
In the citing paper
“because statins, in contrast with novel therapies that specifically target PCSK9, can induce increases in Lp(a) levels.37”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [37]
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 638
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Self-citationTsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 501
Self-citation
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
“Both statins and proprotein convertase subtilisin/kexin Type 9 (PCSK9) inhibitors increase LDLR expression; however, statins increase (slightly, if at all) and PCSK9 inhibitors decrease (by 15– 30%) Lp(a) concentration.(66,151) Some (but not all) in vitro studies indicate that PCSK9 inhibitors decrease hepatic uptake…”
BackgroundAtherosclerosis: Recent developments
Björkegren, J. L. M., & Lusis, A. J. (2022) · Cell · doi:10.1016/j.cell.2022.04.004 · Cited by 1,249
“The treatment resulted in dose-dependent decreases in Lp(a) of up to 80%with no significant adverse events, and larger clinical trials to study functional impacts are underway (Tsimikas et al., 2020).”
BackgroundLipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Self-citationGut Microbiome: Profound Implications for Diet and Disease
Hills, R., Pontefract, B., Mishcon, H., Black, C., Sutton, S., & Theberge, C. (2019) · Nutrients · doi:10.3390/nu11071613 · Cited by 1,092
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
“Of currently approved lipid agents, statins can elevate Lp(a) levels, but are nonetheless considered first-line treatment in patients with high Lp(a) because of their general benefit with respect to elevated ASCVD risk (240).”
Background
Metadata
- Authors
- Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Tsimikas, Sotirios
- Gordts, Philip L S M
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-20
- Volume
- 41
- Issue
- 24
- Pages
- 2275-2284
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2946788429
- Cited by
- 512
- References
- 36
- Citations by year
- 2026: 61 · 2025: 77 · 2024: 85 · 2023: 80 · 2022: 72 · 2021: 60 · 2020: 57 · 2019: 20
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondation Leducq
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- lipoprotein(a), statins, atorvastatin, pravastatin, rosuvastatin, pitavastatin, apolipoprotein(a), residual cardiovascular risk
- MeSH terms
- Rosuvastatin Calcium, Atorvastatin, Humans, Randomized Controlled Trials as Topic, Pravastatin, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin therapy increases lipoprotein(a) levels. https://app.cochat.ai/papers/10.1093/eurheartj/ehz310
- The paper
- Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020). Statin therapy increases lipoprotein(a) levels. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.